Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
32 Results for "
classical pathway
" in MedChemExpress (MCE) Product Catalog:
Products (32)
32 Results for "classical pathway" in MCE Product Catalog:
5
5 Cited Publications
Cat. No.: HY-P1036
CAS No.: 206645-99-0
Target:
Research Areas:
5
5 Cited Publications
Cat. No.: HY-P1036A
Target:
Research Areas:
4
4 Cited Publications
Target:
Research Areas:
TRAF-STOP inhibitor 6877002 is a selective CD40-TRAF6 interaction inhibitor. TRAF-STOP inhibitor 6877002 exerts anti-atherosclerotic activity by blocking the CD40-TRAF6 signaling pathway, inhibiting classical monocyte activation, leukocyte recruitment, and macrophage activation and migration. TRAF-STOP inhibitor 6877002 reduces the phosphorylation levels of signaling intermediates in the canonical NF-κB pathway .
Cat. No.: HY-P99965
CAS No.: 1917321-26-6
Synonyms: SKY59; RO7112689; RG-6107
Target:
Research Areas:
Cat. No.: HY-NP0194A
and non-immune cells. C1q Protein (mouse) can be used for the research of mutiple disease .
Cat. No.: HY-P990091
CAS No.: 2756228-76-7
Synonyms: SAR445088
Target:
Research Areas:
Riliprubart (SAR 445088) is a selective anti-C1s humanized IgG4 monoclonal antibody with mutations that enhance its binding to the neonatal Fc receptor. Riliprubart blocks activation of the classical complement pathway, prevents the formation of the C3 convertase C4b2a, and inhibits complement-mediated hemolytic activity. Riliprubart can be used in research related to classical complement-mediated diseases, cold agglutinin disease, and chronic inflammatory demyelinating polyneuropathy. For the isotype control of Riliprubart, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Cat. No.: HY-P99358
CAS No.: 1662664-56-3
Synonyms: GSK 2398852; Anti-Serum Amyloid P/SAP Reference Antibody (dezamizumab)
Target:
Research Areas:
Cat. No.: HY-P990025
CAS No.: 2579031-19-7
Synonyms: ARGX-117
Target:
Research Areas:
Cat. No.: HY-N2996
CAS No.: 107900-76-5
Category:
Infection Triterpenes Microorganisms Terpenoids Polyporaceae Extract Ganoderma lucidum (Leyss. Ex Fr.) Karst. Plants Disease Research Fields
Target:
Cat. No.: HY-NP0194C
and non-immune cells. C1q Protein (rat) can be used for the research of mutiple disease .
Cat. No.: HY-P10529
CAS No.: 247185-97-3
Target:
Research Areas:
Cat. No.: HY-P10827
CAS No.: 1356469-36-7
Target:
Research Areas:
Research Areas:
AV023 is a potent inhibitor of ANKRD22. AV023 promotes the expansion of gastrointestinal mucosal epithelial stem cells and indirectly activates the Wnt classical pathway, which helps the recovery of damaged gastrointestinal mucosal tissues in the body (extracted from patent CN111205231B) .
Cat. No.: HY-N12265
CAS No.: 108885-62-7
Category:
Human Gut Microbiota Metabolites Viola philippica Cav. Microorganisms Terpenoids Sesquiterpenes Violaceae Extract Plants Endogenous metabolite
Target:
Cat. No.: HY-NP0194B
and non-immune cells. C1q Protein (rabbit) can be used for the research of mutiple disease .
Cat. No.: HY-155851
CAS No.: 444914-19-6
Cat. No.: HY-N19128
CAS No.: 1476801-10-1
Target:
Cat. No.: HY-N19716
CAS No.: 34427-31-1
Category:
Target:
Cat. No.: HY-P992463
Target:
Research Areas:
Cat. No.: HY-N7955
CAS No.: 372096-70-3
Category:
Actaea heracleifolia (Kom.) J. Compton Tetracyclic Triterpenoids Terpenoids Plants Ranunculaceae Extract
Target:
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
